CAMBRIDGE, Mass., Jan. 02, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8th at 1:30 p.m. ET / 10:30 a.m. PT. Following the presentation there will be a Q&A session starting at 2:00 p.m. ET / 11:00 a.m. PT.
The presentation and Q&A session will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation and Q&A session for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



